Amid sluggish sales and dueling lawsuits, Novartis bows out of Amgen partnership, slashes staff
When Novartis and Amgen got Aimovig approved in 2018, most migraine patients relied on decades-old, mildly effective pills to ease their headaches. Proven to reduce migraines by more than 50% in hard-to-treat patients, Aimovig was expected to quickly rake in over $1 billion per year.
In the three years since, though, a slew of rivals have entered: nearly identical treatments from Eli Lilly, Allergan, and Teva, alongside new oral options from Biohaven. Now, with competition tightening and relations between the two tense, Novartis is pulling out of the US market.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.